RxDoctor Payments Data

Melissa Devito

Family · West Islip, NYNPI 1598442808

Payments from drug & device makers

$1,196in general payments, 2019–2025

Across 29 payments — averaging $41.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$478
  • Heartflow, Inc.$180
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$150
  • AbbVie$139
  • Merck$76
  • Exact Sciences$44
  • plus $130 from 6 others

What the payments were for

  • Food & beverage$1,196100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,196 in reported general payments places this provider in the 75th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$69,952
Medicare patients
250
Services billed
2,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin44$57,952
TrulicityDulaglutide19$32,255
FarxigaDapagliflozin Propanediol26$29,960
MounjaroTirzepatide24$28,462
XareltoRivaroxaban18$19,577
OzempicSemaglutide14$17,562
EliquisApixaban15$17,514
RybelsusSemaglutide11$10,988
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$3,802
Novolog FlexpenInsulin Aspart15$2,639
Albuterol Sulfate HfaAlbuterol Sulfate53$1,778
Atorvastatin Calcium208$1,620
Metoprolol Succinate104$1,527
SynthroidLevothyroxine Sodium14$1,516
Nano 2nd Gen Pen NeedlePen Needle, Diabetic14$1,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$22$57,95244 claims
AstraZenecaFarxiga$478$29,96026 claims
Novo NordiskOzempic, Rybelsus$39$28,55025 claims
AbbVieSynthroid$139$1,51614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,883 family providers in New York.

Other family in West Islip

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →